Health and Healthcare
Short Sellers Increase Bets in Major Biotechs
Published:
Last Updated:
The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The January 15 short interest data have been compared with the previous report, and short interest increased in most of these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 9.03 million shares from the previous level of 8.88 million. Shares closed most recently at $150.47, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.85 million from the previous level of 2.57 million. Shares closed most recently at $273.26, within a 52-week range of $254.00 to $480.18.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
